Trials / Completed
CompletedNCT06890611
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimagrumab | Administered SC |
| DRUG | Tirzepatide | Administered SC |
| DRUG | Bimagrumab + Tirzepatide Coformulation | Administered SC |
Timeline
- Start date
- 2025-03-25
- Primary completion
- 2025-09-26
- Completion
- 2025-09-26
- First posted
- 2025-03-24
- Last updated
- 2025-10-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06890611. Inclusion in this directory is not an endorsement.